Navigation Links
Researchers discover chemical that may protect hearts of muscular dystrophy patients
Date:3/15/2010

MINNEAPOLIS / ST. PAUL (March 15, 2010) Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients a fatal and most common form of muscular dystrophy in children.

The chemical, which Medical School scientists have termed a "molecular band-aid," seeks out tiny cuts in diseased heart muscle. When injected into the bloodstream, the molecular band-aid finds these microscopic cuts and protects them from harmful substances so the heart muscle cells can survive and function normally. In order to be effective the chemical must be repeatedly injected, much in the same way a diabetic patient requires regular injections of insulin,

In the March 15 edition of the Journal of Clinical Investigation, Joseph Metzger, Ph.D., professor and chair of the Department of Integrative Biology and Physiology, DeWayne Townsend, D.V.M., Ph.D., assistant professor in the Department of Integrative Biology and Physiology, and colleagues showed the first ever effective long-term treatment for preventing cardiac injury and progressive heart chamber remodeling in a severely affected canine model of muscular dystrophy.

In the study, dystrophic dogs were given the molecular band-aid continuously for two months. The treatment completely blocked cardiac injury and heart disease remodeling compared to the control group of dystrophic canines receiving a placebo.

"The advance in this study is demonstrating that molecular band-aid therapy is a safe and effective approach in preventing heart damage in severely affected large animals with muscular dystrophy," Metzger said.

The hopeful next major step is to determine whether children with muscular dystrophy can be helped by applying the molecular band-aid, first over short periods, then if successful, over the long term with the ultimate goal of enhancing the health and quality of life of muscular dystrophy patients.

Muscular dystrophy causes the muscles in the body to progressively weaken. Duchenne is the most common and severe form of childhood muscular dystrophy. About one of 3,500 boys are born with the crippling disease. Symptoms usually begin in children who are 4-5 years-old, most are in a wheelchair by age 12, and many who have the disease pass away by their late teens to early 20s. The primary causes of death are respiratory failure and heart failure. Current treatments, largely limited to corticosteroids, are minimally effective and can cause serious side effects.

The potential for the molecular band-aid discovery is yet to be fully realized and may be stretched even beyond those who are impacted by muscular dystrophy. Metzger and Townsend believe the molecular band-aid may be applicable in elderly patients who simply have weakened heart muscle. If that is the case, the molecular Band-Aid could be used as a therapy for millions.

"We speculate that certain types of heart damage that occur when we age or when the heart is failing may also someday benefit from molecular band-aid therapy," Townsend said.


'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Researchers recommend curriculum on unhealthy substance use
2. Using new approach, Mayo Clinic researchers find level of gene alters risk of Alzheimers disease
3. Researchers discover brain tumors grow-or-go switch
4. Exposure to BPA may cause permanent fertility defects, Yale researchers find
5. MRI finds tumors in second breast of women diagnosed with cancer in one breast, Mayo researchers say
6. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
7. Learning keeps brain healthy, UCI researchers find
8. Sea Squirt Helps Researchers Test New Alzheimers Drug
9. UMass Lowell researchers findings suggest new ways to diagnose and treat Alzheimers
10. Researchers find that sociodemographic characteristics are related to a patients willingness to participate in cancer screenings
11. Veterans Affairs Researchers Induce a New Transmissible Prion Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: